Report #2862224

Received Sep 30, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: —
Recovered: Unknown
Vaccinated: —
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
RSV	RSV (AREXVY)	GLAXOSMITHKLINE BIOLOGICALS	UNK	UNK	—

Symptoms (1)

Injection site pain

Symptom narrative

Pain at injection site; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of injection site pain in a patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced injection site pain (Verbatim: Pain at injection site). The outcome of the injection site pain was not reported. It was unknown if the reporter considered the injection site pain to be related to Arexvy. It was unknown if the company considered the injection site pain to be related to Arexvy. Additional Information: GSK Receipt Date: 07-SEP-2025 This case was reported by a patient via interactive digital media. The patient had everything was all good except the pain at injection site after the Arexvy vaccine.